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wiOBJECTIVES The purpose of this study is to report the 1-year results of the CENTERA-EU trial.
BACKGROUND The CENTERA transcatheter heart valve (THV) (Edwards Lifesciences, Irvine, California) is a low-proﬁle
(14-F eSheath compatible), self-expanding nitinol valve, with a motorized delivery system allowing for repositionability.
The 30-day results of the CENTERA-EU trial demonstrated the short-term safety and effectiveness of the valve.
METHODS Implantations were completed in 23 centers in Europe, Australia, and New Zealand. Transfemoral access was
used in all patients. Echocardiographic outcomes were adjudicated by a core laboratory at baseline, discharge, 30 days, 6
months, and 1 year. Major adverse clinical events were adjudicated by an independent clinical events committee.
RESULTS Between March 2015 and July 2016, 203 high-risk patients (age 82.7  5.5 years, 67.5% women, 68.0% New
York Heart Association functional class III or IV, Society of Thoracic Surgeons score 6.1  4.2%) with severe, symptomatic
aortic stenosis underwent transcatheter aortic valve replacement with the CENTERA THV. The primary endpoint of
the study was 30-day mortality (1.0%). At 1 year, overall mortality was 9.1%, cardiovascular mortality was 4.6%,
disabling stroke was 4.1%, new permanent pacemakers were implanted in 6.5% of patients at risk, and cardiac-related
rehospitalization was 6.8%. Hemodynamic parameters were stable at 1 year, with a mean aortic valve gradient of 8.1 
4.7 mm Hg, a mean effective oriﬁce area of 1.7  0.42 cm2, and no incidences of severe or moderate aortic regurgitation.
CONCLUSIONS The CENTERA-EU trial demonstrated mid-term safety and effectiveness of the CENTERA THV, with low
mortality, sustained improvements in hemodynamic performances, and low incidence of permanent pacemaker implan-
tations in high-risk patients with symptomatic aortic stenosis. (Safety and Performance of the Edwards CENTERA-EU
Self-Expanding Transcatheter Heart Valve [CENTERA-2]; NCT02458560) (J Am Coll Cardiol Intv 2019;12:673–80)
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CEC = Clinical Events Committee
DVI = Doppler velocity index
EOA = effective oriﬁce area
NYHA = New York Heart
Association
PPM = permanent pacemaker
PVL = paravalvular leak
TAVR = transcatheter aortic
valve replacement
THV = transcatheter heart valve
VI = valve implant
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674T ranscatheter aortic valve replace-ment (TAVR) is established for usein patients with severe, aortic steno-
sis at increased risk for surgery (1). The vast
adoption of TAVR in high-risk patients has
led to an increased interest in the option of
TAVR for lower-risk patients; certain valves
have already received indication for use in
intermediate-risk patients, and trials evalu-
ating TAVR in low-risk patient populations
are ongoing (2–4). As indication for risk level
in TAVR is broadening and patients at lower
risk are receiving valves, the need for
improved outcomes is higher, as lower-riskpatients tend to be younger, have fewer comorbid-
ities, and have a longer life expectancy.SEE PAGE 681Apart from operator experience, one factor critical
to improving outcomes in TAVR is the reﬁnement of
valve technology. The Edwards CENTERA trans-
catheter heart valve (THV) (Edwards Lifesciences,
Irvine, California) is a new self-expanding nitinol
valve with bovine pericardial leaﬂets and a low proﬁle
(14-F eSheath compatible). The CENTERA delivery
system is steerable and motorized, allowing for
repositionability, coaxial alignment with the aortic
annulus, and stable deployment. The CENTERA valve
obtained Conformité Européenne mark in February
2018, based on the 30-day results of the CENTERA-EU
study that have been previously published (5). At 30
days post-implantation, the primary endpoint of
mortality was 1.0%, disabling stroke occurred in 2.5%
of patients, and a new permanent pacemaker (PPM)
was implanted in 4.9% of patients at risk. In addition,
the treatment demonstrated signiﬁcant improvement
in hemodynamics, not only for mean gradient and
effective oriﬁce area (EOA) but also with low rate of
moderate or severe paravalvular aortic regurgitation
(0.6%) at 30 days.
The objective of this publication is to present the
mid-term (1 year) safety and effectiveness of this
novel THV based on the CENTERA-EU trial.as a proctor for Boston Scientiﬁc; has received institutional resea
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VALVE AND DELIVERY SYSTEM. The Edwards
CENTERA THV (sizes 23 mm, 26 mm, and 29 mm)
features a contour-shaped, self-expanding nitinol
valve frame with bovine pericardial tissue leaﬂets (5)
(Figure 1A). The bovine pericardium preparation in-
corporates a proprietary tissue treatment (RESILIA)
that allows dry tissue storage and a <5-min valve
preparation using heparinized saline. The CENTERA
THV is pre-attached to the delivery system and
advanced to the native aortic valve via transfemoral
access using an expandable 14-F inner-diameter
introducer sheath for all valve sizes (Figure 1B). The
delivery system is steerable and motorized, allowing
coaxial alignment within the annulus and stable
deployment. The CENTERA THV is repositionable up
to 80% of its deployment (6).
STUDY DESIGN. Between March 2015 and July 2016,
the CENTERA-EU prospective, multicenter trial
enrolled 203 patients with aortic stenosis at high
surgical risk from 23 centers in Europe, Australia, and
New Zealand. The study was approved by the local
ethics committees, the respective health authorities
in participating countries, and all patients provided a
written informed consent. The study was registered
with ClinicalTrials.gov (NCT02458560).
As per protocol, patients who met eligibility
criteria and for whom TAVR was deemed the best
treatment option by the clinical consensus of the
Heart Team (a multidisciplinary team of cardiac sur-
geons, interventional cardiologists, anesthesiologists,
and cardiac imaging specialists) (5) were enrolled in
this study. Key inclusion and exclusion criteria have
been previously published (5).
An independent Clinical Events Committee (CEC)
reviewed and adjudicated all key clinical events
according to Valve Academic Research Consortium-2
criteria (7). All echocardiographic data were
reviewed by an independent Echo Core Laboratory up
to 1 year (Neil J. Weissman, MD, MedStar Health
Research Institute, Washington, DC).rch grants from St. Jude Medical and Biotronik; and
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FIGURE 1 CENTERA Transcatheter Aortic Valve and Delivery System
(A) Structure of the CENTERA self-expanding transcatheter heart valve. (B) Characteristics of the CENTERA delivery system. PVL ¼ paravalvular leak.
TABLE 1 Baseline Characteristics (N ¼ 203)
As Treated
Age, yrs 82.7  5.5
Female 137 (67.5)
EuroSCORE II (n ¼ 202) 5.1  3.95
STS score 6.1  4.2
NYHA functional class III/IV 138 (68.0)
NYHA functional class IV 12 (5.9)
Previous stroke 19 (9.4)
Coronary artery disease 80 (39.4)
Peripheral vascular disease 30 (14.8)
Renal insufﬁciency 68 (33.5)
Prior pacemaker 16 (7.9)
Incomplete RBBB 17 (8.4)
Atrial ﬁbrillation 40 (19.7)
Porcelain aorta 13 (6.4)
Mean gradient, mm Hg 40.8  13.2
Effective oriﬁce area, cm2 0.7  0.2
LVEF, % 54.6  9.9
Values are mean  SD or n (%).
EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation;
LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association;
RBBB ¼ right bundle branch block; STS ¼ Society of Thoracic Surgeons.
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675A patient was considered to have prosthetic valve
dysfunction if the mean gradient was $20 mm Hg, the
EOA was #0.9 cm2 to 1.1 cm2 or the Doppler velocity
index (DVI) was <0.35, or paravalvular leak (PVL) was
greater than or equal to moderate.
Detailed description of the methods is available in
the published 30-day results (5).
Patients ﬁlled in a quality-of-life Euro-Qol-5D
(Q-5D) questionnaire at baseline and 1 year.
DATA COLLECTION AND STATISTICAL ANALYSIS.
Data collection for this study has been described
previously in the 30-day paper (5). The as-treated
patient population was deﬁned as the patients for
whom the study valve implant (VI) procedure was
begun, and the VI population consisted of all patients
who received an implant and retained the valve upon
leaving the procedure room. Continuous variables are
presented as mean  SD. Categorical variables are
presented as percentage of patients. Freedom from
events was calculated using the Kaplan-Meier
method.
Fisher exact test was used to compare categorical
variables, such as New York Heart Association (NYHA)
functional class and paravalvular regurgitation at
30 days, 6 months, and 1 year to values at baseline.
Mean gradients, EOA, and EQ-5D were analyzed with
a paired t-test. An alpha level of 0.05 was used for all
hypothesis testing. Univariate analysis was per-
formed to assess associations between patient’s
baseline characteristics (NYHA functional class, lo-
gistic EuroSCORE [European System for Cardiac
Operative Risk Evaluation], renal insufﬁciency, atrialﬁbrillation, gradient, body mass index), procedural
(post-dilatation, days in intensive care unit), and
post-procedural complications (acute kidney injury,
new conduction abnormality, major vascular com-
plications, and disabling stroke) with 1-year
mortality.
TABLE 2 Clinical Outcomes at 30 Days and 1 Year in the As-Treated
Population (CEC Adjudicated)
Safety Endpoints
Kaplan-Meier (n ¼ 203)
30 Days 1 Year
All-cause mortality 1.0 (2) 9.1 (18)
Cardiovascular mortality 1.0 (2) 4.6 (9)
Stroke 4.0 (8) 7.6 (15)
Disabling stroke 2.5 (5) 4.1 (8)
Nondisabling stroke 1.5 (3) 4.1 (8)
Myocardial infarction 1.5 (3) 2.0 (4)
New onset atrial ﬁbrillation 8.0 (16) 11.6 (23)
Cardiac-related rehospitalization 0.5 (1) 6.8 (13)
New conduction abnormalities 24.7 (50) 29.4 (59)
Overall PPMI (as treated) 4.9 (10) 6.0 (12)
Naive PPMI (n ¼ 187) 5.4 (10) 6.5 (12)
Life-threatening or disabling bleedings 4.9 (10) NA*
Major bleedings 14.4 (29) NA*
Valve prosthesis endocarditis 0 (0) 0.5 (1)
Structural valve deterioration requiring reintervention 0 (0) 0 (0)
Values are % (n). *Bleedings were adjudicated up to 30 days only.
CEC ¼ Clinical Events Committee; NA ¼ not applicable; PPMI ¼ permanent pacemaker
implantation.
FIGURE 2 Kaplan-
Kaplan-Meier curves
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676Variables with p value < 0.2 in the univariate
model were selected for multivariate stepwise Cox
proportional hazards model for all-cause mortality.
Proportional hazards were checked in the subset
and highly correlated variables were further
removed. Thereafter, a multivariable stepwise Cox
proportional hazards model was computed for
all-cause mortality.Meier Curves to 1 Year
for (A) all-cause and (B) cardiovascular mortality in the CENTERA-EU trial.All statistical analysis was performed using SAS
software version 9.4 (SAS Institute, Cary, North
Carolina).
RESULTS
PATIENT DISPOSITION. The analysis presented was
performed on the as-treated population (n ¼ 203) and
the VI population (n ¼ 198). For this mid-term anal-
ysis, the database of the CENTERA-EU trial was frozen
on January 2018.
Baseline and procedural characteristics are dis-
played in Table 1. Approximately, two-thirds of the
population were female, the mean  SD (minimum to
maximum) Society for Thoracic Surgeons score was
6.1  4.2% (1.4% to 28.0%) and the mean EuroSCORE
II was 5.1  4.0% (0.8% to 27.2%) at baseline. The
mean left ventricular ejection fraction was 54.6% and
7.9% of patients had a PPM at baseline. Device suc-
cess, deﬁned as alive at 3 days and device in proper
anatomic location, was 97.5% (n ¼ 198 of 203).
Between the implantation and 30 days, 3 patients
discontinued the study (1 patient expired due to
cardiac arrest following post-operative bleeding and
vascular complications, 1 patient had cardiac
tamponade that led to death, 1 patient had valve
embolization resulting in a conversion to surgery
and valve explantation). Of the 200 patients eligible
for the 30-day visit, 199 completed the visit within
the time window. Between 30 days and 1 year, a total
of 21 patients exited the study (including 3 with-
drawals, 16 deaths, and 2 explantations). The 2
FIGURE 3 Kaplan-Meier Curve for Permanent Pacemaker Implantation
Permanent pacemaker implantation in the CENTERA-EU trial.
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677explantations were followed until patients’ discon-
tinuation at day 46 and day 285. At 1 year, 179 pa-
tients were eligible for follow-up, and all completed
their 1-year visit.
CLINICAL OUTCOMES TO 1 YEAR. One-year clinical
outcomes are shown in Table 2.
The primary endpoint of all-cause mortality was
1.0% at 30 days and 9.1% at 1 year (Figure 2A).
Cardiovascular mortality was 1.0% at 30 days and
4.6% at 1 year (Figure 2B). The median follow-up for
survival was 391 (interquartile range: 362 to 732)
days. Reasons for cardiovascular death to 1 year (n ¼
9) were stroke (n ¼ 3), decompensated heart failure
(n ¼ 1), cardiogenic shock (n ¼ 1), worsening of heart
failure (n ¼ 1), post-operative bleeding (n ¼ 1),
vascular complications leading to cardiac arrest
(n ¼ 1), and guidewire-related cardiac tamponade
(n ¼ 1). Two of these cardiovascular deaths were
adjudicated as device-related by the CEC: the post-
operative bleeding and an ischemic stroke occurring
on day 304 after the implantation. Reasons for
noncardiovascular death to 1 year (n ¼ 9) were sepsis
(n ¼ 2), renal failure (n ¼ 2), head trauma, gastric
cancer, pneumonia, chronic lymphocyte leukemia,
and metastatic cancer.
At 1 year, 10.6% of patients experienced new onset
atrial ﬁbrillation. A new PPMwas implanted in 6.0% of
patients (Figure 3) and 6.5% of patients at risk
(Table 2), mainly for third-grade atrioventricular block
(9 of 12 cases). The cardiac-related rehospitalization
rate was 6.8%; 2 of the 13 cases were valve related.
Two of the 8 patients with disabling stroke at 1 year
had a prior stroke, 2 had post-dilatation, only 1 had
repositioning, 2 had major vascular complications on
the day of implant, and 2 had new onset atrial ﬁbril-
lation 2 days post-procedure. One of the disabling
strokes was hemorrhagic; the other 7 were ischemic
(Table 3). Three of the patients with disabling stroke
expired from cardiovascular causes; 2 disabling
strokes were device related (Table 3).
Only 32.5% of patients were NYHA functional class
I or II at baseline, whereas 91.2% were in NYHA
functional class I or II at 1 year. The functional status
remained fairly stable from 30 days to 1 year, with
93.0% and 91.3% patients in functional class I or II,
respectively (p ¼ 0.83). Signiﬁcant improvements in
quality of life were observed: the EQ-5D visual analog
score at 1 year was 67.3  17.94 (n ¼ 146), which was
an improvement from the baseline results of 62.0 
16.4 (n ¼ 192) (p ¼ 0.002, paired t-test).
ECHOCARDIOGRAPHIC RESULTS. Echocardiographic
core laboratory evaluation documented a signiﬁcantdecrease in mean transaortic gradients from
40.6  13.3 mm Hg (n ¼ 185) at baseline to 8.1  4.7
mm Hg (n ¼ 147) at 1 year (p < 0.001, paired t-test).
EOA signiﬁcantly increased from 0.7  0.2 cm2
(n ¼ 146) at baseline to 1.7  0.4 cm2 (n ¼ 129) at 1 year
(p < 0.001, paired t-test) (Central Illustration). At 1
year, no central regurgitation was observed, and PVL
was mild or less in all patients. The majority of PVL
was classiﬁed as none or trace (71.4%) (Central
Illustration). The Central Illustration shows a sum-
mary of all subjects, and the p values are from paired
t-tests. At 30 days, only 1 patient was reported with
moderate PVL, but he did not have an echocardio-
gram evaluation at 6 months and 1 year.
There were 2 cases of prosthetic valve dysfunction
reported from 30 days to 1 year. One patient had a
mean gradient of 9.6 mm Hg, EOA of 1.1 cm2, and DVI
of 0.34 at 30 days; nevertheless, the patient presented
with normal hemodynamic values at 6 months with
a mean gradient of 7.8 mm Hg, EOA of 1.7 cm2, and
DVI of 0.43. The other patient, with a mean gradient
of 25.8 mm Hg, EOA of 1.0 cm2, and DVI of 0.31 at
1 year, had a seemingly unrelated adverse event
of peritonitis during the second year in the study.
PREDICTORS OF ALL-CAUSE 1-YEAR MORTALITY.
The predictors of mortality at 1 year were NYHA
functional status at baseline, acute kidney injury at 7
days, and major vascular complications at 30 days.
Baseline atrial ﬁbrillation was found to be predictive
in the univariate analysis only (Table 4).
TABLE 3 Patients Who Experienced Disabling Strokes
Patient #
Type of
Disabling
Stroke
Days
From
Implant Outcome
Antithrombotic
Therapy
Relationship to
Device
1 Ischemic 0 Ongoing Aspirin and clopidogrel No
2 Ischemic 2 Ongoing with hemiparesis
right side
(consent withdrawn)
Not documented No
3 Ischemic 3 Resolved with sequelae
(decreased visual
acuity, persistent mild
left lower limb
weakness, and
moderate left upper
limb weakness)
Antiplatelets and
warfarin
Yes
4 Ischemic 4 Death for cause unknown None No
5 Ischemic 13 Resolved with sequelae
(right arm paralysis
and light ataxia of
the leg)
Platelet aggregation
inhibition therapy
(phenprocoumon) for
1 year then aspirin
No
6 Ischemic 123 Death due to stroke Not documented No
7 Hemorrhagic 203 Death due to stroke None No
8 Ischemic 300 Death due to stroke Aspirin and clopidogrel Yes
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678DISCUSSION
The 1-year follow-up to the 30-day, prospective, multi-
center trial evaluating the CENTERA self-expanding
THV demonstrates a continued safety andLUSTRATION Echocardiographic Parameters
B
seline
2.5
2
1.5
1
0.5
0
6
8.2 7.2 7.5 8.1
.7
1.9 1.9 1.71.8
Effective Orifice Area
(EOA) (cm
2)
Discharge 30 Days 6 Months 1 Year
186 186 166 161 147
147 143 145 136 129
MAVG EOA
. J Am Coll Cardiol Intv. 2019;12(7):673–80.
aortic valve gradient (MAVG) and effective oriﬁce area (EOA). The line grap
and 1 year. Error bars represent SD. (B) Aortic regurgitation at discharge and
line, based on a 2-sided paired t-test with the null hypothesis that there is neffectiveness proﬁle of this new TAVR system for the
treatment of severe aortic stenosis in high-risk pa-
tients. The data support that the CENTERA self-
expanding THV maintains hemodynamic stability up
to 1 year and displays low rates of cardiovascular
mortality and PPM implantation and similar rates of
disabling stroke and cardiac-related rehospitalization.
The low incidence of disabling stroke at 1 year
aligns with results from similar TAVR studies in high-
risk patient populations (8,9). The small number of
disabling stroke (4.1%), and small overall study size
did not provide power for an analysis of predictors
for stroke. In this study, we did not observe any
trends related to potential predictors of stroke,
including prior stroke, post-dilatation (10), valve
repositioning, vascular complications, and new onset
atrial ﬁbrillation (11–14).
The rate of new PPM implantation post-TAVR was
low for patients at risk at 1 year in this study. The
6.5% rate is relatively low when compared with
similar patient populations receiving a TAVR device
(8). There were no cases of sudden cardiac death,
which supports that PPM implantation was not
underused in the study. A potential explanation for
the low PPM rate may be a novel aspect of the valve
design, which keeps the valve high above the left
ventricular outﬂow tract during deployment and100
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Discharge
n = 183
30 Days
n = 165
6 Months
n = 156
1 Year
n = 147
No Severe No Severe No Severe
No Moderate
No Severe
No Moderate
57.4 61.8 64.7 71.4
42.1 37.6 35.3 28.6
0.5 0.6 0 0
Severe Moderate Mild None/Trace
h shows changes in the MAVG (blue) and EOA (red) of patients at
to 1 year. For MAVG and EOA, the p value is <0.001 for all visits
o change from baseline (paired analysis).
TABLE 4 Multivariate Model for 1-Year Mortality
Univariate* Multivariate
HR† p Value HR† p Value
Baseline parameters
NYHA functional class IV vs. other
NYHA functional classes
— 0.002 — 0.002
IV vs. I 6.81 0.120
IV vs. II 0.34 0.210
IV vs. III 0.48 0.334
Log EuroSCORE 0.97 0.30
Renal insufﬁciency 1.25 0.64
Atrial ﬁbrillation 3.47 0.01
Mean aortic valve gradient 1.01 0.55
Body mass index, kg/m2 1.01 0.92
Post-procedural parameters
Post-dilatation 0.74 0.57
Days in ICU 1.02 0.75
Acute kidney injury (#7 days) 5.61 0.02 6.48 0.017
New conduction abnormality (#30 days) 1.19 0.74
Major vascular complications (#30 days) 5.67 0.002 4.60 0.023
Stroke (#30 days) 0 0.99
*All univariates with p value <0.20 were included in the multivariable analyses. †Hazard ratio
(HR) is calculated only for continuous and dichotomous variables.
ICU ¼ intensive care unit; NYHA ¼ New York Heart Association.
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679maintains a high ﬁnal implant position minimizing
overall contact with the conduction system. The
motorized handle of the valve may also be a
contributing factor as it allows for stable delivery and
may provide better control, limiting interactions that
may cause conduction disturbances. Most of the new
pacemakers were implanted within the ﬁrst 7 days
post-procedure, 6 of which were implanted during
the procedure. The remaining 2 were implanted at
days 137 and 330. The timing of new pacemaker
implant is of interest when considering a minimalist
approach to TAVR. Indeed, there is growing interest
in the medical community toward simpliﬁcation of
TAVR procedures to promote better clinical outcomes
and early discharge (15). Our study demonstrates that
in the majority of cases, the need for a new PPM was
identiﬁed within 2 to 3 days post-implant with the
CENTERA THV, which provides conﬁdence for safely
discharging patients from the hospital early. Further
investigation is required to conﬁrm this ﬁnding, but
the initial results are promising.
In addition to a low PPM implantation rate in this
study, the CENTERA valve also demonstrated low
rates of total aortic regurgitation to 1 year (with
three-quarters of patients having none or trace
amounts and none having moderate to severe
amounts). There were no cases of central regurgi-
tation, indicating that leaﬂet coaptation is good to
1 year, and all total aortic regurgitation is para-
valvular. No moderate or greater PVL is notable and
may be attributed to the contoured valve frame
geometry designed for leak prevention. It should
also be noted that one-third of patients in this study
received post-dilation for PVL mitigation with no
associated adverse events. Also, as demonstrated in
the Kim et al. (16) computed tomography sub-
analysis, oversizing for PVL prevention (while per-
formed infrequently in this study) did not increase
the PPM rate. These ﬁndings provide an indication
that, although not always necessary, post-dilatation
and oversizing with the CENTERA valve for PVL
reduction may be performed without trade-offs in
clinical outcomes, particularly PPM or stroke.
The valve performances were good as assessed by
hemodynamic parameters and were remarkably
stable up to 1 year.
STUDY LIMITATIONS. The primary limitation of this
study was the small sample size and lack of
randomization. In addition, the delivery system for
the CENTERA THV evaluated herein is the originaldesign; future studies will evaluate a next-generation
delivery system, which will feature a shorter stiff
distal section for enhanced tracking.
CONCLUSIONS
At 1 year, the CENTERA self-expanding THV main-
tained signiﬁcant hemodynamic improvements from
baseline, and there was no moderate or severe total
aortic regurgitation. In addition, the valve demon-
strated low rates of cardiovascular mortality, un-
precedentedly low rates of PPM implantation, and
rates of disabling stroke and cardiac-related reho-
spitalization similar to other TAVR devices, sup-
porting sustained clinical safety and efﬁcacy with
this valve in a high surgical risk patient cohort.
Further studies in larger patient populations are
required to conﬁrm these ﬁndings, but initial results
are favorable.
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PERSPECTIVES
WHAT IS KNOWN? The 30-day results of the
CENTERA-EU trial demonstrated the safety and effec-
tiveness of this novel self-expanding THV in high-risk
patients undergoing TAVR.
WHAT IS NEW? Low rates of cardiovascular mortality,
stroke, and pacemaker are conﬁrmed at 1 year.
WHAT IS NEXT? These sustained clinical outcomes
could further support the use of this novel THV as a de-
vice of choice in lower risk patients.
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